Table 2.
Main Characteristics and Outcomes of MSC-Based Therapy for Liver Disease
| Study (year) | Liver disease | Patients, sample size (MSC/control) | Cell source | Graft type | Injection route | Cell doses | Duration of follow-up (mo) | Primary outcomes |
|---|---|---|---|---|---|---|---|---|
| Mohamadnejad et al. (2007)35 | Decompensated LC | 4/0 | BM | Auto | PV | 31.7×106 | 12 | MELD score, liver function test, and liver volumes |
| Kharaziha et al. (2009)36 | LC (MELD ≥10) | 8/0 | BM | Auto | Portal vein (n=6) | 3.0–5.0×107 | 6 | MELD score, liver function test, and serum creatinine |
| or PV (n=2) | ||||||||
| Amer et al. (2011)37 | Chronic HCV-associated LC | 20/20 | BM | Auto | 1) IS (n=10) | 2.0×107 | 6 | MELD score, Child-Pugh score, ascites, edema, liver function test, and fatigue |
| 2) IH (n=10) | ||||||||
| Peng et al. (2011)38 | Chronic HBV-associated liver failure | 158/0 | BM | Auto | HA | 1.0×106 | 12 | MELD score, liver function test, and self-reported symptoms |
| El-Ansary et al. (2012)39 | Chronic HCV-associated LC | 15/10 | BM | Auto | PV | 1.0×106 | 12 | MELD score and serum albumin level |
| Shi et al. (2012)40 | Chronic HBV-associated liver failure | 24/19 | UCB | Allo | PV | 0.5×106 | 12 | MELD score, liver function test, and survival rates |
| Zhang et al. (2012)41 | Chronic HBV-associated decompensated LC | 30/15 | UCB | Allo | PV | 0.5×106 | 12 | MELD score, ascites, and liver function test |
| Amin et al. (2013)42 | Chronic HCV-associated LC | 20/0 | BM | Auto | IS | 1.0×107 | 6 | MELD score and liver function test |
| Mohamadnejad et al. (2013)43 | Decompensated LC | 15/12 | BM | Auto | PV | 1.0×106 | 12 | No improvement |
| Wang et al. (2013)44 | UDCA-resistant PBC | 7/0 | UCB | Allo | PV | 0.5×106 | 12 | Serum alkaline phosphatase and γ-GT levels |
| Jang et al. (2014)45 | Alcohol-related LC | 11/0 | BM | Auto | HA | 5.0×107 | 4 | MELD score and liver histology |
| Salama et al. (2014)46 | Chronic HCV-associated LC | 20/20 | BM | Auto | PV | 1.0×106 | 6 | MELD score and Child-Pugh score |
| Wang et al. (2014)47 | UDCA-resistant PBC | 10/0 | BM | Allo | PV | 3.0–5.0×105 | 12 | Serum levels of ALT, AST, γ-GT, and IgM |
| Xu et al. (2014)48 | Chronic HBV-associated LC | 27/29 | BM | Auto | HA | 8.45×105 | 6 | MELD score improvement and reduction in IL-6, IL-17, TNF-α levels |
| Suk et al. (2016)49 | Alcohol-associated LC | 37/18 | BM | Auto | HA | 5.0×107 | 12 | Child-Pugh score and Histologic fibrosis |
| Lanthier et al. (2017)50 | Decompensated alcoholic hepatitis | 28/30 | BM | Auto | HA | 4.7×107 | 1 | No improvement |
| Lin et al. (2017)51 | Chronic HBV-associated liver failure | 56/54 | BM | Allo | PV | 1.0×106 | 6 | MELD score and survival rates |
| Detry et al. (2017)52 | Liver transplant recipients | 10/9 | BM | Allo | PV | 1.5–3.0×106 | 12 | No difference of rate of infection or de novo cancer |
MSC, mesenchymal stem cell; LC, liver cirrhosis; BM, bone marrow; Auto, autogenic transplantation; PV, peripheral vein; MELD, Model for End-Stage Liver Disease; HCV, hepatitis C virus; IS, intrasplenic; IH, intrahepatic; HBV, hepatitis B virus; HA, hepatic artery; UCB, umblical cord blood; Allo, allogenic transplantation; UDCA, ursodeoxycholic acid; PBC, primary biliary cholangitis; γ-GT, γ-glutamyl transferase; ALT, alanine aminotransferase; AST, aspartate transaminase; IgM, immunoglobulin M; IL, interleukin; TNF, tumor necrosis factor.